Residual HIV-1 disease in the era of highly active antiretroviral therapy

New England Journal of Medicine

Volumn 340, Issue 21, 1999, Pages 1672-1674

  Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; HYDROXYUREA; INTERLEUKIN 2; VIRUS DNA; VIRUS RNA;

EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; HIV INFECTIONS; HIV-1; RNA, VIRAL; TRANSCRIPTION, GENETIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 0033609318     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905273402110     Document Type: Editorial

References (20)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:8869-73.
3. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
4. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
5. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-7
6. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4. [Erratum, Science 1997;276:1321.]
7. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-9.
8. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
9. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
10. Martinez M-A, Cababa M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999;256:180-7.
11. Finzi D, Blankson J, Siciliano JD, et al. Latent infection of CD4+T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
12. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990;61:1271-6.
13. Michael NL, Mo T, Merzouki A, et al. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 1995;69:1868-77.
14. Seshamma T, Bagasra O, Trono D, Baltimore D, Pomerantz RJ. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992;89:10663-7.
15. Zhang Z-Q, Schuler T, Wietgrefe S, et al. Sexual transmission and propagation of SIV and HTV-1 in activated and quiescent T cells. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999. Alexandria, Va.: Foundation for Retrovirology and Human Health, 1999:206. abstract.
16. Chun TW, Engel D, Mizell S. Effect of interleukin-2 in diminution of a pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active antiretroviral therapy. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999. Alexandria, Va.: Foundation for Retrovirology and Human Health, 1999:160. abstract.
17. DeBoer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998; 12:1567-70.
18. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352:199-200.
19. Lisziewicz J, Rosenberg B, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340: 1683-4.
20. Pomerantz RJ. HIV in semen and other reservoirs during effective HAART. HIV Adv Res Ther (in press).